LymphomaArchives
Clinical heterogeneity of primary cutaneous ?? T-cell lymphoma: a 20-year single-institution experience
Lymphoma 1 min.
Lymphoma
1 min.
Published on 28/07/2026 |
Original article (Full-text)
| Han, Miran et al. | Blood research. Volume 61(1).
Primary cutaneous γδ T-cell lymphoma (PCGDTCL) is a rare cutaneous T-cell lymphoma defined by γδ T-cell receptor expression and a cytotoxic phenotype. It has historically been considered highly aggressive, with median survival of 15-30 months and no standardized treatment due...
The impact of radiotherapy on the therapeutic response of patients treated with CAR T-cell therapy for high-grade lymphoma: a systematic review
Lymphoma 1 min.
Lymphoma
1 min.
Published on 21/07/2026 |
Original article (Full-text)
| Maïfa
Belghoul
a
b
et al. | Leukemia & Lymphoma 2026; aop:10.1080/10428194.2026.2685253
Chimeric antigen receptor T (CAR -T) cell therapy is a promising form of cancer treatment with proven efficacy in relapsed/refractory lymphomas. However, there are limitations, including toxicity, failure to achieve immunological memory, and immune evasion. The rationale for administering radiotherapy...
